729 related articles for article (PubMed ID: 8790201)
1. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
Schlumberger M; Challeton C; De Vathaire F; Travagli JP; Gardet P; Lumbroso JD; Francese C; Fontaine F; Ricard M; Parmentier C
J Nucl Med; 1996 Apr; 37(4):598-605. PubMed ID: 8691248
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
4. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS).
Schuck A; Biermann M; Pixberg MK; Müller SB; Heinecke A; Schober O; Willich N
Strahlenther Onkol; 2003 Dec; 179(12):832-9. PubMed ID: 14652672
[TBL] [Abstract][Full Text] [Related]
5. [Prospective therapy study in differentiated thyroid carcinoma].
Gemsenjäger E; Heitz P; Martina B
Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
[TBL] [Abstract][Full Text] [Related]
6. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine.
Pacini F; Gasperi M; Fugazzola L; Ceccarelli C; Lippi F; Centoni R; Martino E; Pinchera A
J Nucl Med; 1994 Sep; 35(9):1418-22. PubMed ID: 8071685
[TBL] [Abstract][Full Text] [Related]
7. Outcome after high-dose radioiodine therapy for advanced differentiated thyroid carcinoma in childhood.
Gao YC; Lu HK
Endocr Res; 2009; 34(4):121-9. PubMed ID: 19878072
[TBL] [Abstract][Full Text] [Related]
8. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
Gemsenjäger E; Heitz PU; Martina B; Schweizer I
Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
[TBL] [Abstract][Full Text] [Related]
9. [Long-term course in differentiated thyroid gland carcinoma].
Rösler H; Birrer A; Lüscher D; Kinser J
Schweiz Med Wochenschr; 1992 Nov; 122(48):1843-57. PubMed ID: 1462145
[TBL] [Abstract][Full Text] [Related]
10. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
11. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment.
Bachelot A; Leboulleux S; Baudin E; Hartl DM; Caillou B; Travagli JP; Schlumberger M
Clin Endocrinol (Oxf); 2005 Mar; 62(3):376-9. PubMed ID: 15730423
[TBL] [Abstract][Full Text] [Related]
12. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients.
Dottorini ME; Vignati A; Mazzucchelli L; Lomuscio G; Colombo L
J Nucl Med; 1997 May; 38(5):669-75. PubMed ID: 9170425
[TBL] [Abstract][Full Text] [Related]
13. [Experience with a high-dose therapy concept in metastatic differentiated thyroid cancer].
Grünwald F; Ruhlmann J; Ammari B; Knopp R; Hotze A; Biersack HJ
Nuklearmedizin; 1988 Dec; 27(6):266-71. PubMed ID: 3217257
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
15. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
16. 131I therapy of thyroid cancer patients.
Reiners C; Farahati J
Q J Nucl Med; 1999 Dec; 43(4):324-35. PubMed ID: 10731783
[TBL] [Abstract][Full Text] [Related]
17. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
18. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
20. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
